242
Participants
Start Date
September 15, 2023
Primary Completion Date
April 2, 2025
Study Completion Date
May 7, 2025
Semaglutide
Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
Placebo
Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
National Taiwan University Hospital, Taipei
Taipei Medical University Hospital, Taipei
China Medical University Hospital, Taichung
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City
National Cheng Kung University Hospital, Tainan City
Beijing Hospital, Beijing
The First Bethune hospital of Jilin University-Endocrinology, Changchun
Shanghai Fifth People's Hospital-Endocrinology, Shanghai
Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine, Shanghai
Shanghai Pudong New Area People's Hospital-Endocrinology, Shanghai
The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing
The Second Affiliated Hospital of Nanjing Medical University_Nanjing, Nanjing
The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang
Changzhou No.2 People's Hospital, Yanghu Branch, Changzhou
Jinan Central Hospital, Ji'nan
Fujian Medical University Union Hospital-Endocrinology, Fuzhou
Chongqing University Three Gorges Hospital, Chongqing
Taihe Hospital, Shiyan
Huizhou Central People's Hospital-Endocrinology, Huizhou
Qinghai Provincial People's Hospital, Xining
Lead Sponsor
Novo Nordisk A/S
INDUSTRY